{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:39:11Z","timestamp":1783463951427,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14654-3","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:19:35Z","timestamp":1753456775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Omer Faruk","family":"Kuzu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Bolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Sertesen Camoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal","family":"Karakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhat","family":"Sekmek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadet","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selver","family":"Is\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"G\u00fcnalt\u0131l\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun Fatma","family":"Akkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Tural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagatay","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema Sezin","family":"Goksu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem Nuray","family":"Sever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cengiz","family":"Karacin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali Nahit","family":"Sendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuri","family":"Karadurmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Yeked\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-9887","authenticated-orcid":false,"given":"Y\u00fcksel","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"1","key":"14654_CR1","doi-asserted-by":"publisher","first-page":"102282","DOI":"10.1016\/j.clgc.2024.102282","volume":"23","author":"H B\u00f6lek","year":"2025","unstructured":"B\u00f6lek H, Sertesen E, Kuzu OF, Tural D, Sim S, \u015eendur MAN, et al. Treatment patterns and attrition in metastatic renal cell carcinoma: real-life experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) database. Clin Genitourin Cancer. 2025;23(1):102282.","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"14654_CR2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331.","journal-title":"N Engl J Med"},{"issue":"5","key":"14654_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706\u201320.","journal-title":"Ann Oncol"},{"issue":"9807","key":"14654_CR4","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931\u20139.","journal-title":"Lancet"},{"issue":"6","key":"14654_CR5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"14654_CR6","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1016\/j.clgc.2017.12.005","volume":"16","author":"C Korenbaum","year":"2018","unstructured":"Korenbaum C, Pierard L, Thi\u00e9ry A, Story F, Lindner V, Lang H, et al. Treatments, outcomes, and validity of prognostic scores in patients with sarcomatoid renal cell carcinoma: a 20-year single-institution experience. Clin Genitourin Cancer. 2018;16(3):e577\u201386.","journal-title":"Clin Genitourin Cancer"},{"issue":"18","key":"14654_CR7","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1002\/cncr.33033","volume":"126","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 checkMate 025 trial. Cancer. 2020;126(18):4156\u201367.","journal-title":"Cancer"},{"key":"14654_CR8","doi-asserted-by":"crossref","unstructured":"Bolek H, Yeked\u00fcz E, \u00dcr\u00fcn Y. Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: a systematic review and meta-analysis. Cancer Treat Rev. 2023;122:102667.","DOI":"10.1016\/j.ctrv.2023.102667"},{"issue":"18","key":"14654_CR9","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1056\/NEJMc1400731","volume":"370","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014;370(18):1769\u201370.","journal-title":"N Engl J Med"},{"issue":"14","key":"14654_CR10","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","volume":"32","author":"B Escudier","year":"2014","unstructured":"Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32(14):1412\u20138.","journal-title":"J Clin Oncol"},{"issue":"18\u201319","key":"14654_CR11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/1750743X.2024.2385881","volume":"16","author":"A Damassi","year":"2024","unstructured":"Damassi A, Cremante M, Signori A, Rebuzzi SE, Malgeri A, Napoli MD, et al. Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab. Immunotherapy. 2024;16(18\u201319):1095\u2013103.","journal-title":"Immunotherapy"},{"key":"14654_CR12","doi-asserted-by":"crossref","unstructured":"Ucar G, Acikgoz Y, Ergun Y, Bal O, Yilmaz M, Karakaya S, et al. Sunitinib or pazopanib: is there any difference between tyrosine kinase inhibitors in the pre-nivolumab setting in metastatic renal cell carcinoma? Cureus. 2020;12(9):e10525.","DOI":"10.7759\/cureus.10525"},{"issue":"9","key":"14654_CR13","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1056\/NEJMc1515613","volume":"374","author":"O Huillard","year":"2016","unstructured":"Huillard O, Alexandre J, Goldwasser F, Motzer R, Escudier B, Choueiri T, et al. Treatment of advanced renal-cell carcinoma. N Engl J Med. 2016;374(9):888.","journal-title":"N Engl J Med"},{"issue":"19","key":"14654_CR14","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"1","key":"14654_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1634\/theoncologist.2011-0227","volume":"17","author":"B Shuch","year":"2012","unstructured":"Shuch B, Bratslavsky G, Linehan WM, Srinivasan R. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist. 2012;17(1):46\u201354.","journal-title":"Oncologist"},{"issue":"1","key":"14654_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0022-5347(05)65384-0","volume":"167","author":"BM Mian","year":"2002","unstructured":"Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol. 2002;167(1):65\u201370.","journal-title":"J Urol"},{"issue":"9","key":"14654_CR17","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","volume":"4","author":"AM Goodman","year":"2018","unstructured":"Goodman AM, Piccioni D, Kato S, Boichard A, Wang H-Y, Frampton G, et al. Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncol. 2018;4(9):1237\u201344.","journal-title":"JAMA Oncol"},{"issue":"9","key":"14654_CR18","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41379-019-0269-x","volume":"32","author":"S Gupta","year":"2019","unstructured":"Gupta S, Cheville JC, Jungbluth AA, Zhang Y, Zhang L, Chen Y-B, et al. JAK2\/PD-L1\/PD-L2 (9p24. 1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Mod Pathol. 2019;32(9):1344\u201358.","journal-title":"Mod Pathol"},{"issue":"1","key":"14654_CR19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","volume":"12","author":"Z Bakouny","year":"2021","unstructured":"Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, et al. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021;12(1):808.","journal-title":"Nat Commun"},{"issue":"6","key":"14654_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","volume":"38","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020;38(6):803-17. e4.","journal-title":"Cancer Cell."},{"issue":"24","key":"14654_CR21","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.1002\/cncr.30937","volume":"123","author":"F Kawakami","year":"2017","unstructured":"Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, et al. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017;123(24):4823\u201331.","journal-title":"Cancer"},{"issue":"12","key":"14654_CR22","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/2326-6066.CIR-15-0150","volume":"3","author":"RW Joseph","year":"2015","unstructured":"Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, et al. PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation. Cancer Immunol Res. 2015;3(12):1303\u20137.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"14654_CR23","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","volume":"15","author":"JS Ko","year":"2009","unstructured":"Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148\u201357.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"14654_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/2326-6066.CIR-17-0594","volume":"6","author":"IG Zizzari","year":"2018","unstructured":"Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabr\u00f2 F, Gelibter A, et al. TK inhibitor pazopanib primes DCs by downregulation of the \u03b2-catenin pathway. Cancer Immunol Res. 2018;6(6):711\u201322.","journal-title":"Cancer Immunol Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14654-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14654-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14654-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:47:57Z","timestamp":1757292477000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14654-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14654"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14654-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ankara University Faculty Ethics Committee (date:11\/09\/2024, approval number I09-701\u201324) and it was carried out in accordance with the Code of Ethics of the World Medical Association also known as a declaration of Helsinki. Due to the retrospective nature of the study the use of anonymized data, no informed consent was required as per the ethics committee approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y\u00fcksel \u00dcr\u00fcn: Advisory work \u2014Abdi-\u0130brahim, Astellas, AstraZeneca, Bristol Myers-Squibb, Deva, Eczac\u0131ba\u015f\u0131, Gen ila\u00e7, Gilead, GSK, Janssen, Merck, MSD, Novartis, Pfizer, Roche; travel, honoraria and consultation fees\u2014Abdi-\u0130brahim, Astellas, Bristol Myers-Squibb, Deva, Eczac\u0131ba\u015f\u0131, Gen ila\u00e7, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Roche.All remaining authors have declared no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1220"}}